Find the amount—and see where it came from.
Search a compound to see amounts from named human studies or prescription labels, where available. Each compound page also shows checked public reports separately. A trial group, prescription label, or individual post is not an instruction for a research vial.
Three different kinds of numbers
The table shows a number only when a named human study or finished medicine label supports it. It belongs to that source.
Open “Public reports” on a compound page to see individually linked accounts. A post does not establish a usual or safe amount.
The calculator converts numbers you enter into mL and U-100 marks. It cannot choose an amount or verify a vial.
What if I divide one blend vial into 30 equal daily parts?
These are whole-blend arithmetic examples. They are not reported community ranges, instructions for mixing, or proof that a mixed vial lasts 30 days. Enter a final liquid volume in the calculator to see the corresponding U-100 marks.
18 results
No compounds match those filters. Try another name or clear the filters.
| Compound & vial | Study or medicine-label amount | Source schedule | Evidence | Open the profile |
|---|---|---|---|---|
| BPC-15710 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapBPC-157 evidence review ↗ | Vial math →Public survey → |
| Cagrilintide5 mg vial | 0.3, 0.6, 1.2, 2.4, or 4.5 mg | Once weekly in a phase 2 trial | Human trial groupsCagrilintide phase 2 dose-finding trial (2021) ↗ | Vial math →1 linked public report → |
| CJC-1295 No DAC + Ipamorelin10 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →2 linked public reports → |
| Epitalon50 mg vialEpithalon | No amount established for this research vial | No schedule established for this research vial | Limited human research; different routes2021 AEDG/Epitalon sublingual study ↗ | Vial math →4 linked public reports → |
| GHK-Cu100 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →3 linked public reports → |
| GLOW 70 mg Research Blend70 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →1 linked public report → |
| Glutathione1500 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →1 linked public report → |
| Tirzepatide (JD-2TR)10 mg / 20 mg / 40 mg / 60 mg vialTR2 TR-2 2TR JD-2TR tirzepatide | 2.5–15 mg | Once weekly in adults | Prescription product labelMounjaro prescribing information (2026) ↗ | Vial math →1 linked public report → |
| Retatrutide (JD-3RT)10 mg / 20 mg / 30 mg / 40 mg vialRT3 RT-3 3RT JD-3RT retatrutide | 1, 4, 8, or 12 mg | Once weekly in the phase 2 obesity trial | Human trial groupsRetatrutide phase 2 trial (NEJM, 2023) ↗ | Vial math →1 linked public report → |
| KLOW 80 mg Research Blend80 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →2 linked public reports → |
| KPV10 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →1 linked public report → |
| Melanotan II10 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →1 linked public report → |
| MOTS-C10 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →1 linked public report → |
| NAD+500 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →3 linked public reports → |
| PT-14110 mg vial | 1.75 mg | As needed in the labeled population | Prescription product labelVyleesi (bremelanotide) prescribing information ↗ | Vial math →1 linked public report → |
| Selank10 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →1 linked public report → |
| TB-50010 mg vial | No amount established for this research vial | No schedule established for this research vial | Evidence gapRead evidence notes → | Vial math →1 linked public report → |
| Tesamorelin10 mg vial | 1.28 mg | Once daily for EGRIFTA WR | Prescription product labelEGRIFTA WR prescribing information ↗ | Vial math →1 linked public report → |
Numbers appear only where we identified a prescription label or human study. Those amounts belong to the exact product or study, not to a separately sold research vial. Other rows show the evidence gap. Vial and U-100 calculations are arithmetic from selected inputs, not a validated preparation or personal amount.
New to these terms? Start with the vial basics or read the plain-English definitions for mg, mL, and U-100 marks.